S&P 500   3,326.43 (-0.04%)
DOW   27,227.18 (+0.09%)
QQQ   271.38 (+0.12%)
AAPL   445.32 (+1.15%)
MSFT   212.46 (-0.23%)
FB   253.10 (+1.60%)
GOOGL   1,485.08 (+0.40%)
AMZN   3,187.54 (-0.55%)
NVDA   447.68 (-0.84%)
CGC   18.42 (-4.11%)
BABA   260.11 (-1.81%)
TSLA   1,492.90 (+0.53%)
MU   48.93 (-4.15%)
GE   6.39 (-0.16%)
AMD   85.34 (+0.04%)
T   30.01 (+0.54%)
F   6.94 (-0.29%)
ACB   10.29 (-3.92%)
GILD   68.72 (-0.41%)
NFLX   502.04 (-0.01%)
DIS   128.12 (+0.40%)
BAC   25.48 (+0.35%)
BA   172.45 (-1.05%)
S&P 500   3,326.43 (-0.04%)
DOW   27,227.18 (+0.09%)
QQQ   271.38 (+0.12%)
AAPL   445.32 (+1.15%)
MSFT   212.46 (-0.23%)
FB   253.10 (+1.60%)
GOOGL   1,485.08 (+0.40%)
AMZN   3,187.54 (-0.55%)
NVDA   447.68 (-0.84%)
CGC   18.42 (-4.11%)
BABA   260.11 (-1.81%)
TSLA   1,492.90 (+0.53%)
MU   48.93 (-4.15%)
GE   6.39 (-0.16%)
AMD   85.34 (+0.04%)
T   30.01 (+0.54%)
F   6.94 (-0.29%)
ACB   10.29 (-3.92%)
GILD   68.72 (-0.41%)
NFLX   502.04 (-0.01%)
DIS   128.12 (+0.40%)
BAC   25.48 (+0.35%)
BA   172.45 (-1.05%)
S&P 500   3,326.43 (-0.04%)
DOW   27,227.18 (+0.09%)
QQQ   271.38 (+0.12%)
AAPL   445.32 (+1.15%)
MSFT   212.46 (-0.23%)
FB   253.10 (+1.60%)
GOOGL   1,485.08 (+0.40%)
AMZN   3,187.54 (-0.55%)
NVDA   447.68 (-0.84%)
CGC   18.42 (-4.11%)
BABA   260.11 (-1.81%)
TSLA   1,492.90 (+0.53%)
MU   48.93 (-4.15%)
GE   6.39 (-0.16%)
AMD   85.34 (+0.04%)
T   30.01 (+0.54%)
F   6.94 (-0.29%)
ACB   10.29 (-3.92%)
GILD   68.72 (-0.41%)
NFLX   502.04 (-0.01%)
DIS   128.12 (+0.40%)
BAC   25.48 (+0.35%)
BA   172.45 (-1.05%)
S&P 500   3,326.43 (-0.04%)
DOW   27,227.18 (+0.09%)
QQQ   271.38 (+0.12%)
AAPL   445.32 (+1.15%)
MSFT   212.46 (-0.23%)
FB   253.10 (+1.60%)
GOOGL   1,485.08 (+0.40%)
AMZN   3,187.54 (-0.55%)
NVDA   447.68 (-0.84%)
CGC   18.42 (-4.11%)
BABA   260.11 (-1.81%)
TSLA   1,492.90 (+0.53%)
MU   48.93 (-4.15%)
GE   6.39 (-0.16%)
AMD   85.34 (+0.04%)
T   30.01 (+0.54%)
F   6.94 (-0.29%)
ACB   10.29 (-3.92%)
GILD   68.72 (-0.41%)
NFLX   502.04 (-0.01%)
DIS   128.12 (+0.40%)
BAC   25.48 (+0.35%)
BA   172.45 (-1.05%)
Log in

NASDAQ:AKCAAkcea Therapeutics Stock Price, Forecast & News

$11.28
+0.40 (+3.68 %)
(As of 08/6/2020 11:24 AM ET)
Add
Compare
Today's Range
$11.05
Now: $11.28
$11.33
50-Day Range
$10.84
MA: $13.21
$15.46
52-Week Range
$8.00
Now: $11.28
$23.98
Volume1,539 shs
Average Volume218,459 shs
Market Capitalization$1.14 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.06
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.
Read More
Akcea Therapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.16 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:AKCA
CUSIPN/A
Phone617-207-0202

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$488.54 million
Cash Flow$0.51 per share
Book Value$5.78 per share

Profitability

Net Income$40.77 million

Miscellaneous

Employees248
Market Cap$1.14 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$11.28
+0.40 (+3.68 %)
(As of 08/6/2020 11:24 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive AKCA News and Ratings via Email

Sign-up to receive the latest news and ratings for AKCA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Akcea Therapeutics (NASDAQ:AKCA) Frequently Asked Questions

How has Akcea Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Akcea Therapeutics' stock was trading at $13.44 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AKCA stock has decreased by 16.5% and is now trading at $11.22.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Akcea Therapeutics?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akcea Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Akcea Therapeutics
.

When is Akcea Therapeutics' next earnings date?

Akcea Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Akcea Therapeutics
.

How were Akcea Therapeutics' earnings last quarter?

Akcea Therapeutics Inc (NASDAQ:AKCA) issued its earnings results on Tuesday, August, 4th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.35) by $0.14. The firm had revenue of $22.38 million for the quarter, compared to analysts' expectations of $30.93 million. Akcea Therapeutics had a negative return on equity of 9.04% and a negative net margin of 12.34%. The firm's revenue was down 15.9% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.40) earnings per share.
View Akcea Therapeutics' earnings history
.

What price target have analysts set for AKCA?

4 analysts have issued 12-month price targets for Akcea Therapeutics' stock. Their forecasts range from $24.00 to $41.00. On average, they expect Akcea Therapeutics' share price to reach $34.67 in the next year. This suggests a possible upside of 209.0% from the stock's current price.
View analysts' price targets for Akcea Therapeutics
.

Has Akcea Therapeutics been receiving favorable news coverage?

Media stories about AKCA stock have been trending negative this week, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Akcea Therapeutics earned a coverage optimism score of -2.0 on InfoTrie's scale. They also gave news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days.
View the latest news about Akcea Therapeutics
.

Are investors shorting Akcea Therapeutics?

Akcea Therapeutics saw a drop in short interest in July. As of July 31st, there was short interest totaling 2,850,000 shares, a drop of 8.1% from the July 15th total of 3,100,000 shares. Based on an average trading volume of 284,500 shares, the short-interest ratio is currently 10.0 days. Currently, 17.1% of the shares of the company are short sold.
View Akcea Therapeutics' Current Options Chain
.

Who are some of Akcea Therapeutics' key competitors?

What other stocks do shareholders of Akcea Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akcea Therapeutics investors own include Ionis Pharmaceuticals (IONS), Intelsat (I), Bank of America (BAC), Fossil Group (FOSL), Achaogen (AKAO), Ciena (CIEN), AMC Entertainment (AMC), Apollo Global Management (APO), Associated British Foods (ABF) and Chaarat Gold (CGH).

Who are Akcea Therapeutics' key executives?

Akcea Therapeutics' management team includes the following people:
  • Ms. Paula Soteropoulos, CEO & Director (Age 51)
  • Mr. Michael F. MacLean, Chief Financial Officer (Age 53)
  • Dr. Louis St. Laurence O'Dea FRCPC, MB, BCh, BAO, FRCP(C), Chief Medical Officer (Age 68)
  • Ms. Sarah Boyce, Pres & Director (Age 47)
  • Mr. Jeffrey M. Goldberg, Chief Operating Officer (Age 46)

When did Akcea Therapeutics IPO?

(AKCA) raised $125 million in an initial public offering on Friday, July 14th 2017. The company issued 9,600,000 shares at $12.00-$14.00 per share. Cowen and Company, Stifel and Wells Fargo Securities acted as the underwriters for the IPO and BMO Capital Markets was co-manager.

What is Akcea Therapeutics' stock symbol?

Akcea Therapeutics trades on the NASDAQ under the ticker symbol "AKCA."

Who are Akcea Therapeutics' major shareholders?

Akcea Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Alps Advisors Inc. (0.14%), Swiss National Bank (0.04%), Virtus ETF Advisers LLC (0.04%), SG Americas Securities LLC (0.04%), ProShare Advisors LLC (0.02%) and Hancock Whitney Corp (0.02%). Company insiders that own Akcea Therapeutics stock include Damien Mcdevitt, Jeff Marc Goldberg, Joshua F Patterson, Kyle Jenne, Paula Soteropoulos and Sarah Boyce.
View institutional ownership trends for Akcea Therapeutics
.

Which major investors are selling Akcea Therapeutics stock?

AKCA stock was sold by a variety of institutional investors in the last quarter, including Alps Advisors Inc.. Company insiders that have sold Akcea Therapeutics company stock in the last year include Damien Mcdevitt, Joshua F Patterson, and Kyle Jenne.
View insider buying and selling activity for Akcea Therapeutics
.

Which major investors are buying Akcea Therapeutics stock?

AKCA stock was bought by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Hancock Whitney Corp, Virtus ETF Advisers LLC, Swiss National Bank, ProShare Advisors LLC, and Zurcher Kantonalbank Zurich Cantonalbank .
View insider buying and selling activity for Akcea Therapeutics
.

How do I buy shares of Akcea Therapeutics?

Shares of AKCA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akcea Therapeutics' stock price today?

One share of AKCA stock can currently be purchased for approximately $11.22.

How big of a company is Akcea Therapeutics?

Akcea Therapeutics has a market capitalization of $1.13 billion and generates $488.54 million in revenue each year. The company earns $40.77 million in net income (profit) each year or $0.48 on an earnings per share basis. Akcea Therapeutics employs 248 workers across the globe.

What is Akcea Therapeutics' official website?

The official website for Akcea Therapeutics is www.akceatx.com.

How can I contact Akcea Therapeutics?

Akcea Therapeutics' mailing address is 22 BOSTON WHARF RD 9TH FLOOR, BOSTON MA, 02210. The company can be reached via phone at 617-207-0202 or via email at [email protected]

This page was last updated on 8/6/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.